证券日报网讯华大基因（300676）7月30日在互动平台回答投资者提问时表示，公司主营业务为通过基 因检测、质谱检测、生物信息分析等多组学大数据技术手段，为科研机构、企事业单位、医疗机构、社 会卫生组织等提供研究服务和精准医学检测综合解决方案。公司暂无增发或配股融资的计划。 ...

Group 1 - The core business of the company includes gene testing, mass spectrometry testing, bioinformatics analysis, and medical AI models, providing comprehensive solutions for research services, precision medical testing, and health management [2] - The company has received multiple awards, including the "2023 Chinese Preventive Medicine Association Science and Technology Award" and recognition in the ESG field for its management practices [2] - The latest financial report shows a revenue of 672 million yuan for Q1 2025, a year-on-year decrease of 18.18%, and a net loss of approximately 52.7 million yuan, with a gross profit margin of 43.55% [3] Group 2 - As of May 29, the company's stock closed at 52.26 yuan, up 3.83%, with a latest price-to-book ratio of 2.39 and a total market capitalization of 21.731 billion yuan [1] - On May 29, the company experienced a net inflow of main funds amounting to 13.51 million yuan, with a total inflow of 57.99 million yuan over the past five days [1] - The company's price-to-earnings ratio (TTM) is -22.45, indicating a negative earnings performance compared to the industry average of 49.64 [3]

Core Insights - The company, BGI Genomics, reported a significant decline in its financial performance for 2024, with a net profit loss of 903 million yuan, marking its first annual net loss since its listing and the largest loss to date [1][2] Financial Performance - BGI Genomics achieved a revenue of 3.867 billion yuan in 2024, a year-on-year decrease of 11.10% [1] - The net profit attributable to shareholders was a loss of 903 million yuan, representing a staggering year-on-year decline of 1071.68% [1][2] - The company's net profit had peaked at 2.09 billion yuan in 2020, but has been on a downward trend since, with profits of 1.462 billion yuan in 2021, 803 million yuan in 2022, and 93 million yuan in 2023 [2] - Total assets decreased to 12.542 billion yuan, down 7.87% year-on-year, while net assets attributable to shareholders fell to 9.135 billion yuan, a reduction of 7.35% [2] Business Segment Performance - The infection prevention business saw a dramatic revenue drop of 85.91%, with earnings of only 73 million yuan in 2024 compared to 516 million yuan in 2023 [3] - Despite the downturn in the infection prevention segment, the reproductive health and oncology businesses maintained growth, with the precision medicine testing solutions segment showing a 22.37% increase when excluding the impact of public health events [3] Industry Outlook - The global genetic testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a compound annual growth rate of 10.81% [4] - The company plans to increase investments in medical AI models, intelligent testing platforms, and integrated multi-omics technologies to enhance its core competitiveness and adapt to market changes [4]